These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 12485956

  • 1. Metabolism, pharmacokinetics, and excretion of a highly selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in human cytochrome P450 2D6 extensive and poor metabolizers.
    Johnson K, Shah A, Jaw-Tsai S, Baxter J, Prakash C.
    Drug Metab Dispos; 2003 Jan; 31(1):76-87. PubMed ID: 12485956
    [Abstract] [Full Text] [Related]

  • 2. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
    Taylor TJ, Diringer K, Russell T, Venkatakrishnan K, Wilner K, Crownover PH, Benincosa LJ, Gibbs MA.
    Clin Pharmacokinet; 2006 Jan; 45(10):989-1001. PubMed ID: 16984212
    [Abstract] [Full Text] [Related]

  • 3. Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteers.
    Prakash C, Cui D, Baxter JG, Bright GM, Miceli J, Wilner K.
    Drug Metab Dispos; 1998 May; 26(5):448-56. PubMed ID: 9571226
    [Abstract] [Full Text] [Related]

  • 4. Metabolism, distribution and excretion of a selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in rats and dogs.
    Prakash C, Cui D, Potchoiba MJ, Butler T.
    Drug Metab Dispos; 2007 Aug; 35(8):1350-64. PubMed ID: 17496205
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetic and tolerability profile of pridopidine in healthy-volunteer poor and extensive CYP2D6 metabolizers, following single and multiple dosing.
    Lindskov Krog P, Osterberg O, Gundorf Drewes P, Rembratt Å, Schultz A, Timmer W.
    Eur J Drug Metab Pharmacokinet; 2013 Mar; 38(1):43-51. PubMed ID: 22948856
    [Abstract] [Full Text] [Related]

  • 6. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
    Zhou SF.
    Clin Pharmacokinet; 2009 Mar; 48(11):689-723. PubMed ID: 19817501
    [Abstract] [Full Text] [Related]

  • 7. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.
    Lefebvre J, Poirier L, Poirier P, Turgeon J, Lacourciere Y.
    Br J Clin Pharmacol; 2007 May; 63(5):575-82. PubMed ID: 17094780
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
    Preskorn S, Patroneva A, Silman H, Jiang Q, Isler JA, Burczynski ME, Ahmed S, Paul J, Nichols AI.
    J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
    [Abstract] [Full Text] [Related]

  • 9. Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study.
    Zawertailo LA, Kaplan HL, Busto UE, Tyndale RF, Sellers EM.
    J Clin Psychopharmacol; 1998 Aug; 18(4):332-7. PubMed ID: 9690700
    [Abstract] [Full Text] [Related]

  • 10. Brexpiprazole Pharmacokinetics in CYP2D6 Poor Metabolizers: Using Physiologically Based Pharmacokinetic Modeling to Optimize Time to Effective Concentrations.
    Elmokadem A, Bruno CD, Housand C, Jordie EB, Chow CR, Lesko LJ, Greenblatt DJ.
    J Clin Pharmacol; 2022 Jan; 62(1):66-75. PubMed ID: 34328221
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of venlafaxine extended release 75  mg and desvenlafaxine 50  mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.
    Nichols AI, Focht K, Jiang Q, Preskorn SH, Kane CP.
    Clin Drug Investig; 2011 Jan; 31(3):155-67. PubMed ID: 21288052
    [Abstract] [Full Text] [Related]

  • 12. Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers.
    Pedersen RS, Damkier P, Brøsen K.
    Eur J Clin Pharmacol; 2006 Jul; 62(7):513-21. PubMed ID: 16763825
    [Abstract] [Full Text] [Related]

  • 13. The effects of tramadol on static and dynamic pupillometry in healthy subjects--the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status.
    Fliegert F, Kurth B, Göhler K.
    Eur J Clin Pharmacol; 2005 Jun; 61(4):257-66. PubMed ID: 15906019
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype.
    García-Quetglas E, Azanza JR, Sádaba B, Muñoz MJ, Gil I, Campanero MA.
    Pharmacol Res; 2007 Feb; 55(2):122-30. PubMed ID: 17175164
    [Abstract] [Full Text] [Related]

  • 15. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine.
    Brøsen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF.
    Eur J Clin Pharmacol; 1993 Feb; 44(4):349-55. PubMed ID: 8513845
    [Abstract] [Full Text] [Related]

  • 16. The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine.
    Gross AS, Phillips AC, Rieutord A, Shenfield GM.
    Br J Clin Pharmacol; 1996 Apr; 41(4):311-7. PubMed ID: 8730977
    [Abstract] [Full Text] [Related]

  • 17. Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?
    Dorne JL, Walton K, Slob W, Renwick AG.
    Food Chem Toxicol; 2002 Nov; 40(11):1633-56. PubMed ID: 12176090
    [Abstract] [Full Text] [Related]

  • 18. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation.
    Jones DR, Gorski JC, Haehner BD, O'Mara EM, Hall SD.
    Clin Pharmacol Ther; 1996 Oct; 60(4):374-84. PubMed ID: 8873685
    [Abstract] [Full Text] [Related]

  • 19. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.
    Zhen Y, Slanar O, Krausz KW, Chen C, Slavík J, McPhail KL, Zabriskie TM, Perlík F, Gonzalez FJ, Idle JR.
    Drug Metab Dispos; 2006 Sep; 34(9):1563-74. PubMed ID: 16782768
    [Abstract] [Full Text] [Related]

  • 20. Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.
    Nichols AI, Lobello K, Guico-Pabia CJ, Paul J, Preskorn SH.
    J Clin Psychopharmacol; 2009 Aug; 29(4):383-6. PubMed ID: 19593180
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.